Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms21217833 http://scihub22266oqcxt.onion/10.3390/ijms21217833 33105763!7660105!33105763     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2020 ; 21 (21): ä Nephropedia Template TP {{tp|p=33105763|t=2020. Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection |pdf=|usr=}}{{33105763}} gab.com Text Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33105763 #FOAvip The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre- and post- glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism. Twit Text FOAVip Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=33105763 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33105763 #FOAvip English Wikipedia <ref>{{Cite pmid|33105763}}</ref> Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection #MMPMID33105763 Hou YC; Zheng CM; Yen TH; Lu KC Int J Mol Sci 2020[Oct]; 21 (21): ä PMID33105763show ga The development of sodium-glucose transporter 2 inhibitor (SGLT2i) broadens the therapeutic strategies in treating diabetes mellitus. By inhibiting sodium and glucose reabsorption from the proximal tubules, the improvement in insulin resistance and natriuresis improved the cardiovascular mortality in diabetes mellitus (DM) patients. It has been known that SGLT2i also provided renoprotection by lowering the intraglomerular hypertension by modulating the pre- and post- glomerular vascular tone. The application of SGLT2i also provided metabolic and hemodynamic benefits in molecular aspects. The recent DAPA-CKD trial and EMPEROR-Reduced trial provided clinical evidence of renal and cardiac protection, even in non-DM patients. Therefore, the aim of the review is to clarify the hemodynamic and metabolic modulation of SGLT2i from the molecular mechanism. |Animals[MESH] |Anti-Inflammatory Agents, Non-Steroidal/pharmacology[MESH] |Autonomic Nervous System Diseases/*drug therapy/physiopathology[MESH] |Cardio-Renal Syndrome/*drug therapy/physiopathology[MESH] |Clinical Trials as Topic[MESH] |Diabetes Mellitus/*drug therapy/physiopathology[MESH] |Glomerular Filtration Rate[MESH] |Hemodynamics/drug effects[MESH] |Humans[MESH] |Ketosis/chemically induced[MESH] |Kidney Glomerulus/physiopathology[MESH] |Sodium-Glucose Transporter 2 Inhibitors/*pharmacology[MESH]Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection (epmc).pdf DeepDyve Pubget Overpricing